EDAP - EDAP TMS S.A.
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 10.07 |
| Open | 10.16 |
| Bid | 9.85 x 1200 |
| Ask | 10.80 x 1200 |
| Day's Range | 9.96 - 10.17 |
| 52 Week Range | 6.02 - 12.65 |
| Volume | |
| Avg. Volume | 69,346 |
| Market Cap | 373.336M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | Aug 22, 2023 - Aug 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.98 |
Fair Value
Related Research
GlobeNewswireEDAP to Present at the Jefferies Healthcare Conference
LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference, which is being held June 7-9, 2023, in New York City. Presentation details: Date:Wednesday, June 7Time:1:30-1:55 PM ET in Track 2Webcast:https://wsw.com/webcast/jeff281/edap/1821820 The live and archived
- GlobeNewswire
EDAP Announces First Quarter 2023 Financial Results
- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17that 8:30 am EDT - LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023. “After achieving record results in the fourth quarter of 2022, we continued to see growing demand t
Simply Wall St.EDAP TMS S.A. (NASDAQ:EDAP) Not Flying Under The Radar
You may think that with a price-to-sales (or "P/S") ratio of 6.9x EDAP TMS S.A. ( NASDAQ:EDAP ) is a stock to avoid...
- GlobeNewswire
EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023
- Company to host conference call and webcast on Wednesday, May 17that 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2023 before the markets open on Wednesday, May 17th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financia
- GlobeNewswire
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
Meeting to Showcase EDAP’s Focal One® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the Company will be showcasing its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists
- GlobeNewswire
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that the Company will host a webcast that will feature a live procedure broadcast of its Focal One HIFU as a potential treatment for ablating cancer tissue in patients who are diagnosed with pros
- GlobeNewswire
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
Allows for market launch of the only micro-ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today provided a regulatory and clinical update. The Company has received approval from the Pharmaceutical and Medical Devices Agency (“PMDA”) for the commercialization of the ExactVu™ micro-ultrasound biopsy platform in Japan. “We are pleased to announce the approval of the Exa
Insider MonkeyEDAP TMS S.A. (NASDAQ:EDAP) Q4 2022 Earnings Call Transcript
EDAP TMS S.A. (NASDAQ:EDAP) Q4 2022 Earnings Call Transcript March 30, 2023 Operator: Ladies and gentlemen, greetings, and welcome to the EDAP TMS Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participant lines are in a listen-only mode. As a reminder, this conference is being recorded. It is now my […]
- GlobeNewswire
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as compared to EUR 9.9 million (USD 11.7 million) for the full-year 2021Record Q4 2022 total revenue of EUR 15.7 million ($16.2 million) versus EUR 14.0 million ($15.9 million) for Q4 2021Ended the year with a strong cash position of EUR 63.1 million ($67.5 million) as of December 31, 2022Ryan Rhodes to suc
InvestorPlace7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive d
- GlobeNewswire
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP) The HIFU treated arm showed significant benefits across multiple side effect and quality-of-life measures LYON, France, March 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a recent presentation of positive results from a large, multicenter, non-in
ZacksSentinelOne (S) to Report Q4 Earnings: What's in the Cards?
Sentinel One's (S) fourth-quarter fiscal 2023 results are likely to reflect the benefits of strategic integrations and expanding clientele.
- GlobeNewswire
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financ
- GlobeNewswire
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
Record full-year 2022 total preliminary unaudited revenue of €55.1 million ($58.0 million) represents an increase of 25.1% over full-year 2021, driven by 58.1% HIFU growth Record Q4 2022 total preliminary unaudited revenue of €15.8 million ($16.2 million) versus €14.0 million ($15.9 million) for Q4 2021 Maintains strong balance sheet with cash and cash equivalents of €63.1 million ($67.5 million) as of December 31, 2022 LYON, France, February 14, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”
- GlobeNewswire
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)Positive safety profile with 96.7% of patients with no or non-significant adverse events Data was presented at the Paris Santé Femmes Major Gynecology French Congress on Friday, January 27 Company intends to initiate randomized, double-blind, SHAM-controlled study in 2Q 2023 LYON, France, January 31, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic ene
- Simply Wall St.
Those who invested in EDAP TMS (NASDAQ:EDAP) five years ago are up 301%
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...
- GlobeNewswire
EDAP Announces Record Q4 US Focal One Placements
Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company experienced robust demand for its Focal One HIFU technology in the fourth quarter of 2022, placing nine Focal One machines in the U.S. The breadth of new placements also continues to be strong, comprising a mix of both academic medical centers an
- Simply Wall St.
While institutions own 28% of EDAP TMS S.A. (NASDAQ:EDAP), individual investors are its largest shareholders with 58% ownership
If you want to know who really controls EDAP TMS S.A. ( NASDAQ:EDAP ), then you'll have to look at the makeup of its...
Insider MonkeyEDAP TMS S.A. (NASDAQ:EDAP) Q3 2022 Earnings Call Transcript
EDAP TMS S.A. (NASDAQ:EDAP) Q3 2022 Earnings Call Transcript November 17, 2022 Operator: Greetings and welcome to EDAP TMS Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to […]
- Simply Wall St.
Estimating The Intrinsic Value Of EDAP TMS S.A. (NASDAQ:EDAP)
Today we will run through one way of estimating the intrinsic value of EDAP TMS S.A. ( NASDAQ:EDAP ) by estimating the...
- GlobeNewswire
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company’s U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating la
- GlobeNewswire
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
Study to begin enrolling patients in Q2 2023 Endometriosis represents significant expansion opportunity for Focal One LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French authorities to initiate a Phase 3 randomized, controlled clinical trial evaluating Focal One high intensity focused ultrasound (HIFU) as a potential treatment for rectal deep infiltra
ZacksEDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's Why
EDAP TMS S.A. (EDAP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ZacksZacks.com featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares
Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares are part of the Zacks Screen of the Week article.
ZacksBest Momentum Stocks to Buy for November 21st
ACR, EDAP and H made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 21, 2022.